Related Experiment Video
Updated: May 20, 2026
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
Published on: June 18, 2013
Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance
Alexandre Ho-Pun-Cheung1, Hervé Bazin, Nadège Gaborit
1Translational Research Unit, CRLC Val d'Aurelle Paul Lamarque, Montpellier, France.
Abstract:
Following the development of targeted therapies against EGFR and HER2, two members of the human epidermal receptor (HER) family of receptor tyrosine kinases, much interest has been focused on their expression in tumors. However, knowing the expression levels of individual receptors may not be sufficient to predict drug response. Here, we describe the development of antibody-based time-resolved Förster resonance energy transfer (TR-FRET) assays for the comprehensive analysis not only of EGFR and HER2 expression in tumor cryosections, but also of their activation through quantification of HER homo- or heterodimers. First, EGFR and HER2 expression levels were quantified in 18 breast tumors and the results were compared with those obtained by using reference methods. The EGFR number per cell determined by TR-FRET was significantly correlated with EGFR mRNA copy number (P<0.0001). Moreover, our method detected HER2 overexpression with 100% specificity and sensibility, as confirmed by the standard IHC, FISH and qPCR analyses. EGFR and HER2 dimerization was then assessed, using as controls xenograft tumors from cell lines with known dimer expression profiles. Our results show that quantification of HER dimerization provides information about receptor activation that cannot be obtained by quantification of single receptors. Quantifying HER expression and dimerization by TR-FRET assays might help identifying novel clinical markers for optimizing patients' treatment in oncology.
Insights
New TR-FRET assays quantify human epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) expression and dimerization in tumors. This method offers a more comprehensive analysis for potential clinical markers in oncology.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- Targeted therapies for EGFR and HER2 are crucial in cancer treatment.
- Assessing individual receptor levels alone may not predict drug response effectively.
- Understanding receptor activation through dimerization is key for treatment optimization.
Purpose of the Study:
- To develop and validate antibody-based time-resolved Förster resonance energy transfer (TR-FRET) assays.
- To comprehensively analyze EGFR and HER2 expression and dimerization in tumor cryosections.
- To explore novel clinical markers for optimizing cancer patient treatment.
Main Methods:
- Development of antibody-based TR-FRET assays.
- Quantification of EGFR and HER2 expression in 18 breast tumors.
- Assessment of EGFR and HER2 homo- and heterodimerization using TR-FRET.
- Comparison with reference methods (IHC, FISH, qPCR).
Main Results:
- TR-FRET assay showed significant correlation between EGFR number per cell and EGFR mRNA copy number (P<0.0001).
- The method achieved 100% specificity and sensitivity in detecting HER2 overexpression.
- Quantification of HER dimerization provided insights into receptor activation beyond single receptor levels.
Conclusions:
- TR-FRET assays enable precise quantification of HER receptor expression and dimerization.
- HER dimerization analysis offers critical information on receptor activation.
- This approach may identify novel biomarkers for personalized cancer therapy.
